Revenue (Annual)

Revenue: The sum of all revenue fields included for a company's operating activities.

ADMA Biologics Inc (ADMA) had Revenue of $426.45M for the most recently reported fiscal year, ending 2024-12-31.

Quarterly Annual

Figures for fiscal year ending 2024-12-31

Income Statement Financials
Revenue	$426.45M
Net Income	$197.67M
Cost of Goods Sold	$206.90M
Gross Profit	$219.55M
Operating Expenses	$287.47M
Operating Income	$138.98M
Non-Operating Income/Expense	$-13.27M
Pre-Tax Income	$125.71M
Normalized Pre-Tax Income	$125.71M
Income after Taxes	$197.67M
Income from Continuous Operations	$197.67M
Consolidated Net Income/Loss	$197.67M
Normalized Income after Taxes	$197.67M
EBIT	$138.98M
EBITDA	$147.84M
Weighted-Average Shares Outstanding (Basic)	233.08M
Weighted-Average Shares Outstanding (Diluted)	243.34M
Earnings per Share (EPS) (Basic)	$0.85
Earnings per Share (EPS) (Diluted)	$0.81
Balance Sheet Financials
Current Assets	$331.41M
Property, Plant, and Equipment	$54.71M
Long-Term Assets	$157.27M
Total Assets	$488.68M
Current Liabilities	$55.54M
Long-Term Debt	$80.90M
Long-Term Liabilities	$84.12M
Total Liabilities	$139.66M
Common Equity	$349.02M
Tangible Shareholders Equity	$345.03M
Shareholders Equity	$349.02M
Common Shares Outstanding	236.62M
Cash Flow Statement Financials
Cash Flow from Operating Activities	$118.67M
Cash Flow from Investing Activities	$-8.57M
Cash Flow from Financial Activities	$-58.30M
Beginning Cash	$51.35M
End Cash	$103.15M
Increase/Decrease in Cash	$51.80M
Stock-Based Compensation	$13.62M
Common Stock Dividends Paid	--
Preferred Stock Dividends Paid	--
Fundamental Metrics & Ratios
Current Ratio	5.97
Non-Performing Assets / Total Loans	--
Loan Loss Reserves / Non-Performing Loans	--
Debt to Capital Ratio	0.19
Debt to Equity Ratio	0.24
Gross Margin	51.48%
Operating Margin	32.59%
EBIT Margin	32.59%
EBITDA Margin	34.67%
Pre-Tax Profit Margin	29.48%
Profit Margin	46.35%
Free Cash Flow	$110.45M
Loss Ratio	--
Expense Ratio	--
Combined Ratio	--
Asset Turnover	0.87
Inventory Turnover	1.22
Receiveable Turnover	8.53
Days Sales in Receivables	42.79
Return on Equity	56.64%
Return on Tangible Equity	57.29%
Return on Assets	40.45%
Return on Investments	45.98%
Book Value Per Share	$1.48
Free Cash Flow per Share	$0.45
Operating Cash Flow per Share	$0.49

Data from Zacks Investment Research, Inc.